Clostridium difficile toxins A and B: Insights into pathogenic properties and extraintestinal effects

Toxins

Volumn 8, Issue 5, 2016, Pages

  Di Bella, Stefano ^a   Ascenzi, Paolo ^b   Siarakas, Steven ^c   Petrosillo, Nicola ^a   di Masi, Alessandra ^b  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b ROMA TRE UNIVERSITY   (Italy)

^c ANZAC Research Institute   (Australia)

Author keywords

Clostridium difficile; Pathogenesis; Toxins

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; CYSTEINE PROTEINASE; GAMMA INTERFERON; GUANOSINE TRIPHOSPHATASE; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 23; MYELOID DIFFERENTIATION FACTOR 88; MYELOPEROXIDASE; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PROTEOCHONDROITIN SULFATE; REGULATOR PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; URIDINE DIPHOSPHATE GLUCOSE; BACTERIAL PROTEIN; BACTERIAL TOXIN; ENTEROTOXIN; TCDA PROTEIN, CLOSTRIDIUM DIFFICILE; TOXB PROTEIN, CLOSTRIDIUM DIFFICILE;

APOPTOSIS; CHANNEL GATING; CLOSTRIDIUM DIFFICILE INFECTION; CRYSTAL STRUCTURE; CYTOPATHOGENIC EFFECT; CYTOTOXICITY; DNA SEQUENCE; ENDOCYTOSIS; ENZYME GLYCOSYLATION; GENE EXPRESSION REGULATION; GENE INACTIVATION; HEART FAILURE; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOCOMPROMISED PATIENT; INTESTINE INJURY; KIDNEY DISEASE; NEUROLOGIC DISEASE; PATHOGENICITY; RECEPTOR BINDING; REVIEW; TIGHT JUNCTION; TOXEMIA; ANIMAL; CHEMISTRY; CLOSTRIDIUM INFECTION; GENETICS;

ANIMALS; BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM INFECTIONS; ENTEROTOXINS; HUMANS; TOXEMIA;

EID: 84965062532     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins8050134     Document Type: Review

References (188)

1. Magill, S. S.; Edwards, J. R.; Bamberg, W.; Beldavs, Z. G.; Dumyati, G.; Kainer, M. A.; Lynfield, R.; Maloney, M.; McAllister-Hollod, L.; Nadle, J.; et al. Multistate point-prevalence survey of health care-associated infections. N. Engl. J. Med. 2014, 370, 1198-1208. [CrossRef] [PubMed]
2. Bartlett, J. G.; Gerding, D. N. Clinical recognition and diagnosis of Clostridium difficile infection. Clin. Infect. Dis. 2008, 46, S12-S18. [CrossRef] [PubMed]
3. Redelings, M. D.; Sorvillo, F.; Mascola, L. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg. Infect. Dis. 2007, 13, 1417-1419. [CrossRef] [PubMed]
4. Burns, D. A.; Heap, J. T.; Minton, N. P. Clostridium difficile spore germination: An update. Res. Microbiol. 2010, 161, 730-734. [CrossRef] [PubMed]
5. Anthony, D. M.; Reynolds, T.; Paton, J.; Rafter, L. Serum albumin in risk assessment for Clostridium difficile. J. Hosp. Infect. 2009, 71, 378-379. [CrossRef] [PubMed]
6. Miller, M. A.; Louie, T.; Mullane, K.; Weiss, K.; Lentnek, A.; Golan, Y.; Kean, Y.; Sears, P. Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. BMC Infect. Dis. 2013, 13, 148. [CrossRef] [PubMed]
7. Islam, J.; Taylor, A. L.; Rao, K.; Huffnagle, G.; Young, V. B.; Rajkumar, C.; Cohen, J.; Papatheodorou, P.; Aronoff, D. M.; Llewelyn, M. J. The role of the humoral immune response to Clostridium difficile toxins A and B in susceptibility to Clostridium difficile infection: A case-control study. Anaerobe 2014, 27, 82-86. [CrossRef] [PubMed]
8. Di Bella, S.; Friedrich, A. W.; Garcia-Almodovar, E.; Gallone, M. S.; Taglietti, F.; Topino, S.; Galati, V.; Johnson, E.; D’Arezzo, S.; Petrosillo, N. Clostridium difficile infection among hospitalized HIV-infected individuals: Epidemiology and risk factors: Results from a case-control study (2002-2013). BMC Infect. Dis. 2015, 15, 194. [CrossRef] [PubMed]
9. Leffler, D. A.; Lamont, J. T. Clostridium difficile infection. N. Engl. J. Med. 2015, 373, 287-288. [PubMed]
10. Vardakas, K. Z.; Polyzos, K. A.; Patouni, K.; Rafailidis, P. I.; Samonis, G.; Falagas, M. E. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: A systematic review of the evidence. Int. J. Antimicrob. Agents 2012, 40, 1-8. [CrossRef] [PubMed]
11. Bakken, J. S.; Borody, T.; Brandt, L. J.; Brill, J. V.; Demarco, D. C.; Franzos, M. A.; Kelly, C.; Khoruts, A.; Louie, T.; Martinelli, L. P.; et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin. Gastroenterol. Hepatol. 2011, 9, 1044-1049. [CrossRef] [PubMed]
12. Warny, M.; Pepin, J.; Fang, A.; Killgore, G.; Thompson, A.; Brazier, J.; Frost, E.; McDonald, L. C. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005, 366, 1079-1084. [CrossRef]
13. Rupnik, M.; Wilcox, M. H.; Gerding, D. N. Clostridium difficile infection: New developments in epidemiology and pathogenesis. Nat. Rev. Microbiol. 2009, 7, 526-536. [CrossRef] [PubMed]
14. Quesada-Gomez, C.; Lopez-Urena, D.; Chumbler, N.; Kroh, H. K.; Castro-Pena, C.; Rodriguez, C.; Orozco-Aguilar, J.; Gonzalez-Camacho, S.; Rucavado, A.; Guzman-Verri, C.; et al. Analysis of TcdB proteins within the hypervirulent clade 2 reveals an impact of RhoA glucosylation on Clostridium difficile proinflammatory activities. Infect. Immun. 2016, 84, 856-865. [CrossRef] [PubMed]
15. Carman, R. J.; Stevens, A. L.; Lyerly, M. W.; Hiltonsmith, M. F.; Stiles, B. G.; Wilkins, T. D. Clostridium difficile binary toxin (CDT) and diarrhea. Anaerobe 2011, 17, 161-165. [CrossRef] [PubMed]
16. Jank, T.; Belyi, Y.; Aktories, K. Bacterial glycosyltransferase toxins. Cell. Microbiol. 2015, 17, 1752-1765. [CrossRef] [PubMed]
17. Jank, T.; Giesemann, T.; Aktories, K. Rho-glucosylating Clostridium difficile toxins A and B: New insights into structure and function. Glycobiology 2007, 17, 15R-22R. [CrossRef] [PubMed]
18. Pruitt, R. N.; Lacy, D. B. Toward a structural understanding of Clostridium difficile toxins A and B. Front. Cell. Infect. Microbiol. 2012, 2, 28. [CrossRef] [PubMed]
19. Gerding, D. N.; Johnson, S.; Rupnik, M.; Aktories, K. Clostridium difficile binary toxin CDT: Mechanism, epidemiology, and potential clinical importance. Gut Microbes 2014, 5, 15-27. [CrossRef] [PubMed]
20. Knapp, O.; Benz, R.; Popoff, M. R. Pore-forming activity of clostridial binary toxins. Biochim. Biophys. Acta 2016, 1858, 512-525. [CrossRef] [PubMed]
21. Braun, V.; Hundsberger, T.; Leukel, P.; Sauerborn, M.; von Eichel-Streiber, C. Definition of the single integration site of the pathogenicity locus in Clostridium difficile. Gene 1996, 181, 29-38. [CrossRef]
22. Hammond, G. A.; Johnson, J. L. The toxigenic element of Clostridium difficile strain CPI 10463. Microb. Pathog. 1995, 19, 203-213. [CrossRef]
23. Hundsberger, T.; Braun, V.; Weidmann, M.; Leukel, P.; Sauerborn, M.; von Eichel-Streiber, C. Transcription analysis of the genes tcda-e of the pathogenicity locus of Clostridium difficile. Eur. J. Biochem. 1997, 244, 735-742. [CrossRef] [PubMed]
24. Mani, N.; Dupuy, B. Regulation of toxin synthesis in Clostridium difficile by an alternative RNA polymerase sigma factor. Proc. Natl. Acad. Sci. USA 2001, 98, 5844-5849. [CrossRef] [PubMed]
25. Tan, K. S.; Wee, B. Y.; Song, K. P. Evidence for holin function of tcde gene in the pathogenicity of Clostridium difficile. J. Med. Microbiol. 2001, 50, 613-619. [CrossRef] [PubMed]
26. Govind, R.; Dupuy, B. Secretion of Clostridium difficile toxins A and B requires the holin-like protein TcdE. PLoS Pathog. 2012, 8, e1002727. [CrossRef] [PubMed]
27. Olling, A.; Seehase, S.; Minton, N. P.; Tatge, H.; Schroter, S.; Kohlscheen, S.; Pich, A.; Just, I.; Gerhard, R. Release of TcdA and TcdB from Clostridium difficile cdi 630 is not affected by functional inactivation of the tcdE gene. Microb. Pathog. 2012, 52, 92-100. [CrossRef] [PubMed]
28. Govind, R.; Fitzwater, L.; Nichols, R. Observations on the role of TcdE isoforms in Clostridium difficile toxin secretion. J. Bacteriol. 2015, 197, 2600-2609. [CrossRef] [PubMed]
29. Matamouros, S.; England, P.; Dupuy, B. Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol. Microbiol. 2007, 64, 1274-1288. [CrossRef] [PubMed]
30. Cartman, S. T.; Kelly, M. L.; Heeg, D.; Heap, J. T.; Minton, N. P. Precise manipulation of the Clostridium difficile chromosome reveals a lack of association between the TcdC genotype and toxin production. Appl. Environ. Microbiol. 2012, 78, 4683-4690. [CrossRef] [PubMed]
31. Bakker, D.; Smits, W. K.; Kuijper, E. J.; Corver, J. TcdC does not significantly repress toxin expression in Clostridium difficile 630DErm. PLoS ONE 2012, 7, e43247. [CrossRef] [PubMed]
32. Just, I.; Selzer, J.; Wilm, M.; von Eichel-Streiber, C.; Mann, M.; Aktories, K. Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature 1995, 375, 500-503. [CrossRef] [PubMed]
33. Hofmann, F.; Busch, C.; Prepens, U.; Just, I.; Aktories, K. Localization of the glucosyltransferase activity of Clostridium difficile toxin B to the N-terminal part of the holotoxin. J. Biol. Chem. 1997, 272, 11074-11078. [PubMed]
34. Chumbler, N. M.; Rutherford, S. A.; Zhang, Z.; Farrow, M. A.; Lisher, J. P.; Farquhar, E.; Giedroc, D. P.; Spiller, B.; Melnyk, R. A.; Lacy, D. B. Crystal structure of Clostridium difficile toxin A. Nat. Microbiol. 2016, 1, 1-6. [CrossRef]
35. Genisyuerek, S.; Papatheodorou, P.; Guttenberg, G.; Schubert, R.; Benz, R.; Aktories, K. Structural determinants for membrane insertion, pore formation and translocation of Clostridium difficile toxin B. Mol. Microbiol. 2011, 79, 1643-1654. [CrossRef] [PubMed]
36. Von Eichel-Streiber, C.; Sauerborn, M.; Kuramitsu, H. K. Evidence for a modular structure of the homologous repetitive C-terminal carbohydrate-binding sites of Clostridium difficile toxins and Streptococcus mutans glucosyltransferases. J. Bacteriol. 1992, 174, 6707-6710. [PubMed]
37. Manse, J. S.; Baldwin, M. R. Binding and entry of Clostridium difficile toxin B is mediated by multiple domains. FEBS Lett. 2015, 589, 3945-3951. [CrossRef] [PubMed]
38. Pruitt, R. N.; Chagot, B.; Cover, M.; Chazin, W. J.; Spiller, B.; Lacy, D. B. Structure-function analysis of inositol hexakisphosphate-induced autoprocessing in Clostridium difficile toxin A. J. Biol. Chem. 2009, 284, 21934-21940. [CrossRef] [PubMed]
39. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF chimera-A visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25, 1605-1612. [CrossRef] [PubMed]
40. Elliott, B.; Chang, B. J.; Golledge, C. L.; Riley, T. V. Clostridium difficile-associated diarrhoea. Intern. Med. J. 2007, 37, 561-568. [CrossRef] [PubMed]
41. Brouwer, M. S.; Roberts, A. P.; Hussain, H.; Williams, R. J.; Allan, E.; Mullany, P. Horizontal gene transfer converts non-toxigenic Clostridium difficile strains into toxin producers. Nat. Commun. 2013, 4, 2601. [CrossRef] [PubMed]
42. Dingle, K. E.; Elliott, B.; Robinson, E.; Griffiths, D.; Eyre, D. W.; Stoesser, N.; Vaughan, A.; Golubchik, T.; Fawley, W. N.; Wilcox, M. H.; et al. Evolutionary history of the Clostridium difficile pathogenicity locus. Genome Biol. Evol. 2014, 6, 36-52. [CrossRef] [PubMed]
43. Onderdonk, A. B.; Johnston, J.; Mayhew, J. W.; Gorbach, S. L. Effect of dissolved oxygen and Eh and Bacteroides fragilis during continuous culture. Appl. Environ. Microbiol. 1976, 31, 168-172. [PubMed]
44. Yamakawa, K.; Karasawa, T.; Ikoma, S.; Nakamura, S. Enhancement of Clostridium difficile toxin production in biotin-limited conditions. J. Med. Microbiol. 1996, 44, 111-114. [CrossRef] [PubMed]
45. Karlsson, S.; Dupuy, B.; Mukherjee, K.; Norin, E.; Burman, L. G.; Akerlund, T. Expression of Clostridium difficile toxins A and B and their sigma factor TcdD is controlled by temperature. Infect. Immun. 2003, 71, 1784-1793. [CrossRef] [PubMed]
46. Bouillaut, L.; Dubois, T.; Sonenshein, A. L.; Dupuy, B. Integration of metabolism and virulence in Clostridium difficile. Res. Microbiol. 2015, 166, 375-383. [CrossRef] [PubMed]
47. Dupuy, B.; Sonenshein, A. L. Regulated transcription of Clostridium difficile toxin genes. Mol. Microbiol. 1998, 27, 107-120. [CrossRef] [PubMed]
48. Karlsson, S.; Lindberg, A.; Norin, E.; Burman, L. G.; Akerlund, T. Toxins, butyric acid, and other short-chain fatty acids are coordinately expressed and down-regulated by cysteine in Clostridium difficile. Infect. Immun. 2000, 68, 5881-5888. [CrossRef] [PubMed]
49. Karasawa, T.; Maegawa, T.; Nojiri, T.; Yamakawa, K.; Nakamura, S. Effect of arginine on toxin production by Clostridium difficile in defined medium. Microbiol. Immunol. 1997, 41, 581-585. [CrossRef] [PubMed]
50. Karlsson, S.; Burman, L. G.; Akerlund, T. Suppression of toxin production in Clostridium difficile VPI 10463 by amino acids. Microbiology 1999, 145, 1683-1693. [CrossRef] [PubMed]
51. Fujita, Y. Carbon catabolite control of the metabolic network in Bacillus subtilis. Biosci. Biotechnol. Biochem. 2009, 73, 245-259. [CrossRef] [PubMed]
52. Sonenshein, A. L. Cody, a global regulator of stationary phase and virulence in Gram-positive bacteria. Curr. Opin. Microbiol. 2005, 8, 203-207. [CrossRef] [PubMed]
53. Brekasis, D.; Paget, M. S. A novel sensor of NADH/NAD+ redox poise in Streptomyces coelicolor A3(2). EMBO J. 2003, 22, 4856-4865. [CrossRef] [PubMed]
54. Pruitt, R. N.; Chambers, M. G.; Ng, K. K.; Ohi, M. D.; Lacy, D. B. Structural organization of the functional domains of Clostridium difficile toxins A and B. Proc. Natl. Acad. Sci. USA 2010, 107, 13467-13472. [CrossRef] [PubMed]
55. Davies, A. H.; Roberts, A. K.; Shone, C. C.; Acharya, K. R. Super toxins from a super bug: Structure and function of Clostridium difficile toxins. Biochem. J. 2011, 436, 517-526. [CrossRef] [PubMed]
56. Voth, D. E.; Ballard, J. D. Clostridium difficile toxins: Mechanism of action and role in disease. Clin. Microbiol. Rev. 2005, 18, 247-263. [CrossRef] [PubMed]
57. Jank, T.; Aktories, K. Structure and mode of action of clostridial glucosylating toxins: The ABCD model. Trends Microbiol. 2008, 16, 222-229. [CrossRef] [PubMed]
58. Rupnik, M.; Pabst, S.; Rupnik, M.; von Eichel-Streiber, C.; Urlaub, H.; Soling, H. D. Characterization of the cleavage site and function of resulting cleavage fragments after limited proteolysis of Clostridium difficile toxin B (TcdB) by host cells. Microbiology 2005, 151, 199-208. [CrossRef] [PubMed]
59. Yuan, P.; Zhang, H.; Cai, C.; Zhu, S.; Zhou, Y.; Yang, X.; He, R.; Li, C.; Guo, S.; Li, S.; et al. Chondroitin sulfate proteoglycan 4 functions as the cellular receptor for Clostridium difficile toxin B. Cell Res. 2015, 25, 157-168. [CrossRef] [PubMed]
60. Egerer, M.; Giesemann, T.; Jank, T.; Satchell, K. J.; Aktories, K. Auto-catalytic cleavage of Clostridium difficile toxins A and B depends on cysteine protease activity. J. Biol. Chem. 2007, 282, 25314-25321. [CrossRef] [PubMed]
61. Olling, A.; Goy, S.; Hoffmann, F.; Tatge, H.; Just, I.; Gerhard, R. The repetitive oligopeptide sequences modulate cytopathic potency but are not crucial for cellular uptake of Clostridium difficile toxin A. PLoS ONE 2011, 6, e17623. [CrossRef] [PubMed]
62. Reinert, D. J.; Jank, T.; Aktories, K.; Schulz, G. E. Structural basis for the function of Clostridium difficile toxin B. J. Mol. Biol. 2005, 351, 973-981. [CrossRef] [PubMed]
63. Mesmin, B.; Robbe, K.; Geny, B.; Luton, F.; Brandolin, G.; Popoff, M. R.; Antonny, B. A phosphatidylserine-binding site in the cytosolic fragment of Clostridium sordellii lethal toxin facilitates glucosylation of membrane-bound Rac and is required for cytotoxicity. J. Biol. Chem. 2004, 279, 49876-49882. [CrossRef] [PubMed]
64. Geissler, B.; Tungekar, R.; Satchell, K. J. Identification of a conserved membrane localization domain within numerous large bacterial protein toxins. Proc. Natl. Acad. Sci. USA 2010, 107, 5581-5586. [CrossRef] [PubMed]
65. Pruitt, R. N.; Chumbler, N. M.; Rutherford, S. A.; Farrow, M. A.; Friedman, D. B.; Spiller, B.; Lacy, D. B. Structural determinants of Clostridium difficile toxin A glucosyltransferase activity. J. Biol. Chem. 2012, 287, 8013-8020. [CrossRef] [PubMed]
66. Murase, T.; Eugenio, L.; Schorr, M.; Hussack, G.; Tanha, J.; Kitova, E. N.; Klassen, J. S.; Ng, K. K. Structural basis for antibody recognition in the receptor-binding domains of toxins A and B from Clostridium difficile. J. Biol. Chem. 2014, 289, 2331-2343. [CrossRef] [PubMed]
67. Barth, H.; Pfeifer, G.; Hofmann, F.; Maier, E.; Benz, R.; Aktories, K. Low pH-induced formation of ion channels by Clostridium difficile toxin B in target cells. J. Biol. Chem. 2001, 276, 10670-10676. [CrossRef] [PubMed]
68. Spyres, L. M.; Daniel, J.; Hensley, A.; Qa’Dan, M.; Ortiz-Leduc, W.; Ballard, J. D. Mutational analysis of the enzymatic domain of Clostridium difficile toxin B reveals novel inhibitors of the wild-type toxin. Infect. Immun. 2003, 71, 3294-3301. [CrossRef] [PubMed]
69. Jank, T.; Reinert, D. J.; Giesemann, T.; Schulz, G. E.; Aktories, K. Change of the donor substrate specificity of Clostridium difficile toxin B by site-directed mutagenesis. J. Biol. Chem. 2005, 280, 37833-37838. [CrossRef] [PubMed]
70. Chaves-Olarte, E.; Weidmann, M.; Eichel-Streiber, C.; Thelestam, M. Toxins A and B from Clostridium difficile differ with respect to enzymatic potencies, cellular substrate specificities, and surface binding to cultured cells. J. Clin. Investig. 1997, 100, 1734-1741. [CrossRef] [PubMed]
71. Kreimeyer, I.; Euler, F.; Marckscheffel, A.; Tatge, H.; Pich, A.; Olling, A.; Schwarz, J.; Just, I.; Gerhard, R. Autoproteolytic cleavage mediates cytotoxicity of Clostridium difficile toxin A. Naunyn Schmiedebergs Arch. Pharmacol. 2011, 383, 253-262. [CrossRef] [PubMed]
72. Chaves-Olarte, E.; Low, P.; Freer, E.; Norlin, T.; Weidmann, M.; von Eichel-Streiber, C.; Thelestam, M. A novel cytotoxin from Clostridium difficile serogroup F is a functional hybrid between two other large clostridial cytotoxins. J. Biol. Chem. 1999, 274, 11046-11052. [CrossRef] [PubMed]
73. Lim, S. K.; Stuart, R. L.; Mackin, K. E.; Carter, G. P.; Kotsanas, D.; Francis, M. J.; Easton, M.; Dimovski, K.; Elliott, B.; Riley, T. V.; et al. Emergence of a ribotype 244 strain of Clostridium difficile associated with severe disease and related to the epidemic ribotype 027 strain. Clin. Infect. Dis. 2014, 58, 1723-1730. [CrossRef] [PubMed]
74. Raaijmakers, J. H.; Bos, J. L. Specificity in Ras and Rap signaling. J. Biol. Chem. 2009, 284, 10995-10999. [CrossRef] [PubMed]
75. Huelsenbeck, J.; Dreger, S.; Gerhard, R.; Barth, H.; Just, I.; Genth, H. Difference in the cytotoxic effects of toxin B from Clostridium difficile strain VPI 10463 and toxin B from variant Clostridium difficile strain 1470. Infect. Immun. 2007, 75, 801-809. [CrossRef] [PubMed]
76. Krivan, H. C.; Clark, G. F.; Smith, D. F.; Wilkins, T. D. Cell surface binding site for Clostridium difficile enterotoxin: Evidence for a glycoconjugate containing the sequence Gala1-3Gal, B1-4GlcNAc. Infect. Immun. 1986, 53, 573-581. [PubMed]
77. Von Eichel-Streiber, C.; Sauerborn, M. Clostridium difficile toxin A carries a C-terminal repetitive structure homologous to the carbohydrate binding region of streptococcal glycosyltransferases. Gene 1990, 96, 107-113. [CrossRef]
78. Ho, J. G.; Greco, A.; Rupnik, M.; Ng, K. K. Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A. Proc. Natl. Acad. Sci. USA 2005, 102, 18373-18378. [CrossRef] [PubMed]
79. Dingle, T.; Wee, S.; Mulvey, G. L.; Greco, A.; Kitova, E. N.; Sun, J.; Lin, S.; Klassen, J. S.; Palcic, M. M.; Ng, K. K.; et al. Functional properties of the carboxy-terminal host cell-binding domains of the two toxins, TcdA and TcdB, expressed by Clostridium difficile. Glycobiology 2008, 18, 698-706. [CrossRef] [PubMed]
80. Demarest, S. J.; Salbato, J.; Elia, M.; Zhong, J.; Morrow, T.; Holland, T.; Kline, K.; Woodnutt, G.; Kimmel, B. E.; Hansen, G. Structural characterization of the cell wall binding domains of Clostridium difficile toxins A and B; evidence that Ca2+ plays a role in toxin A cell surface association. J. Mol. Biol. 2005, 346, 1197-1206. [CrossRef] [PubMed]
81. Greco, A.; Ho, J. G.; Lin, S. J.; Palcic, M. M.; Rupnik, M.; Ng, K. K. Carbohydrate recognition by Clostridium difficile toxin A. Nat. Struct. Mol. Biol. 2006, 13, 460-461. [CrossRef] [PubMed]
82. Reineke, J.; Tenzer, S.; Rupnik, M.; Koschinski, A.; Hasselmayer, O.; Schrattenholz, A.; Schild, H.; von Eichel-Streiber, C. Autocatalytic cleavage of Clostridium difficile toxin B. Nature 2007, 446, 415-419. [CrossRef] [PubMed]
83. Albesa-Jove, D.; Bertrand, T.; Carpenter, E. P.; Swain, G. V.; Lim, J.; Zhang, J.; Haire, L. F.; Vasisht, N.; Braun, V.; Lange, A.; et al. Four distinct structural domains in Clostridium difficile toxin B visualized using SAXS. J. Mol. Biol. 2010, 396, 1260-1270. [CrossRef] [PubMed]
84. Chumbler, N. M.; Farrow, M. A.; Lapierre, L. A.; Franklin, J. L.; Haslam, D. B.; Goldenring, J. R.; Lacy, D. B. Clostridium difficile Toxin B causes epithelial cell necrosis through an autoprocessing-independent mechanism. PLoS Pathog. 2012, 8, e1003072. [CrossRef]
85. Lanis, J. M.; Barua, S.; Ballard, J. D. Variations in TcdB activity and the hypervirulence of emerging strains of Clostridium difficile. PLoS Pathog. 2010, 6, e1001061. [CrossRef] [PubMed]
86. Shen, A.; Lupardus, P. J.; Gersch, M. M.; Puri, A. W.; Albrow, V. E.; Garcia, K. C.; Bogyo, M. Defining an allosteric circuit in the cysteine protease domain of Clostridium difficile toxins. Nat. Struct. Mol. Biol. 2011, 18, 364-371. [CrossRef] [PubMed]
87. Florin, I.; Thelestam, M. Internalization of Clostridium difficile cytotoxin into cultured human lung fibroblasts. Biochim. Biophys. Acta 1983, 763, 383-392. [CrossRef]
88. Qa’Dan, M.; Spyres, L. M.; Ballard, J. D. pH-induced conformational changes in Clostridium difficile toxin B. Infect. Immun. 2000, 68, 2470-2474. [CrossRef] [PubMed]
89. Hamza, T.; Zhang, Z.; Melnyk, R. A.; Feng, H. Defective mutations within the translocation domain of Clostridium difficile toxin B impair disease pathogenesis. Pathog. Dis. 2016, 74, ftv098. [CrossRef] [PubMed]
90. Papatheodorou, P.; Zamboglou, C.; Genisyuerek, S.; Guttenberg, G.; Aktories, K. Clostridial glucosylating toxins enter cells via clathrin-mediated endocytosis. PLoS ONE 2010, 5, e10673. [CrossRef] [PubMed]
91. Pothoulakis, C.; Galili, U.; Castagliuolo, I.; Kelly, C. P.; Nikulasson, S.; Dudeja, P. K.; Brasitus, T. A.; LaMont, J. T. A human antibody binds to alpha-galactose receptors and mimics the effects of Clostridium difficile toxin A in rat colon. Gastroenterology 1996, 110, 1704-1712. [CrossRef] [PubMed]
92. Na, X.; Kim, H.; Moyer, M. P.; Pothoulakis, C.; LaMont, J. T. Gp96 is a human colonocyte plasma membrane binding protein for Clostridium difficile toxin A. Infect. Immun. 2008, 76, 2862-2871. [CrossRef] [PubMed]
93. LaFrance, M. E.; Farrow, M. A.; Chandrasekaran, R.; Sheng, J.; Rubin, D. H.; Lacy, D. B. Identification of an epithelial cell receptor responsible for Clostridium difficile TcdB-induced cytotoxicity. Proc. Natl. Acad. Sci. USA 2015, 112, 7073-7078. [CrossRef] [PubMed]
94. Goy, S. D.; Olling, A.; Neumann, D.; Pich, A.; Gerhard, R. Human neutrophils are activated by a peptide fragment of Clostridium difficile toxin B presumably via formyl peptide receptor. Cell. Microbiol. 2015, 17, 893-909. [CrossRef] [PubMed]
95. Schorch, B.; Song, S.; van Diemen, F. R.; Bock, H. H.; May, P.; Herz, J.; Brummelkamp, T. R.; Papatheodorou, P.; Aktories, K. Lrp1 is a receptor for Clostridium perfringens TpeL toxin indicating a two-receptor model of clostridial glycosylating toxins. Proc. Natl. Acad. Sci. USA 2014, 111, 6431-6436. [CrossRef] [PubMed]
96. Egerer, M.; Giesemann, T.; Herrmann, C.; Aktories, K. Autocatalytic processing of Clostridium difficile toxin B. Binding of inositol hexakisphosphate. J. Biol. Chem. 2009, 284, 3389-3395. [CrossRef] [PubMed]
97. Just, I.; Selzer, J.; von Eichel-Streiber, C.; Aktories, K. The low molecular mass GTP-binding protein Rho is affected by toxin A from Clostridium difficile. J. Clin. Investig. 1995, 95, 1026-1031. [CrossRef] [PubMed]
98. Yang, Z.; Zhang, Y.; Huang, T.; Feng, H. Glucosyltransferase activity of Clostridium difficile toxin B is essential for disease pathogenesis. Gut Microbes 2015, 6, 221-224. [CrossRef] [PubMed]
99. Burridge, K.; Wennerberg, K. Rho and Rac take center stage. Cell 2004, 116, 167-179. [CrossRef]
100. Jaffe, A. B.; Hall, A. Rho GTPases: Biochemistry and biology. Annu. Rev. Cell Dev. Biol. 2005, 21, 247-269. [CrossRef] [PubMed]
101. Lemichez, E.; Aktories, K. Hijacking of Rho GTPases during bacterial infection. Exp. Cell Res. 2013, 319, 2329-2336. [CrossRef] [PubMed]
102. Popoff, M. R. Bacterial factors exploit eukaryotic Rho GTPase signaling cascades to promote invasion and proliferation within their host. Small GTPases. 2014, 5, e983863. [CrossRef] [PubMed]
103. Chen, S.; Sun, C.; Wang, H.; Wang, J. The role of Rho GTPases in toxicity of Clostridium difficile toxins. Toxins 2015, 7, 5254-5267. [CrossRef] [PubMed]
104. Sehr, P.; Joseph, G.; Genth, H.; Just, I.; Pick, E.; Aktories, K. Glucosylation and ADP ribosylation of Rho proteins: Effects on nucleotide binding, GTPase activity, and effector coupling. Biochemistry 1998, 37, 5296-5304. [CrossRef] [PubMed]
105. Genth, H.; Aktories, K.; Just, I. Monoglucosylation of RhoA at threonine 37 blocks cytosol-membrane cycling. J. Biol. Chem. 1999, 274, 29050-29056. [CrossRef] [PubMed]
106. Chaves-Olarte, E.; Freer, E.; Parra, A.; Guzman-Verri, C.; Moreno, E.; Thelestam, M. R-Ras glucosylation and transient RhoA activation determine the cytopathic effect produced by toxin B variants from toxin A-negative strains of Clostridium difficile. J. Biol. Chem. 2003, 278, 7956-7963. [CrossRef] [PubMed]
107. Ottlinger, M. E.; Lin, S. Clostridium difficile toxin B induces reorganization of actin, vinculin, and talin in cultured cells. Exp. Cell Res. 1988, 174, 215-229. [CrossRef]
108. Triadafilopoulos, G.; Pothoulakis, C.; O'Brien, M. J.; LaMont, J. T. Differential effects of Clostridium difficile toxins A and B on rabbit ileum. Gastroenterology 1987, 93, 273-279. [PubMed]
109. Hecht, G.; Pothoulakis, C.; LaMont, J. T.; Madara, J. L. Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers. J. Clin. Investig. 1988, 82, 1516-1524. [CrossRef] [PubMed]
110. Moore, R.; Pothoulakis, C.; LaMont, J. T.; Carlson, S.; Madara, J. L. C. Difficile toxin A increases intestinal permeability and induces Cl-secretion. Am. J. Physiol. 1990, 259, G165-G172. [PubMed]
111. Hecht, G.; Koutsouris, A.; Pothoulakis, C.; LaMont, J. T.; Madara, J. L. Clostridium difficile toxin B disrupts the barrier function of T84 monolayers. Gastroenterology 1992, 102, 416-423. [PubMed]
112. Johal, S. S.; Solomon, K.; Dodson, S.; Borriello, S. P.; Mahida, Y. R. Differential effects of varying concentrations of Clostridium difficile toxin A on epithelial barrier function and expression of cytokines. J. Infect. Dis. 2004, 189, 2110-2119. [CrossRef] [PubMed]
113. Just, I.; Gerhard, R. Large clostridial cytotoxins. Rev. Physiol. Biochem. Pharmacol. 2004, 152, 23-47. [PubMed]
114. Yang, G.; Zhou, B.; Wang, J.; He, X.; Sun, X.; Nie, W.; Tzipori, S.; Feng, H. Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium. BMC Microbiol. 2008, 8, 192. [CrossRef] [PubMed]
115. Gerhard, R.; Tatge, H.; Genth, H.; Thum, T.; Borlak, J.; Fritz, G.; Just, I. Clostridium difficile toxin A induces expression of the stress-induced early gene product rhob. J. Biol. Chem. 2005, 280, 1499-1505. [CrossRef] [PubMed]
116. Genth, H.; Huelsenbeck, J.; Hartmann, B.; Hofmann, F.; Just, I.; Gerhard, R. Cellular stability of Rho-GTPases glucosylated by Clostridium difficile toxin B. FEBS Lett. 2006, 580, 3565-3569. [CrossRef] [PubMed]
117. Ng, J.; Hirota, S. A.; Gross, O.; Li, Y.; Ulke-Lemee, A.; Potentier, M. S.; Schenck, L. P.; Vilaysane, A.; Seamone, M. E.; Feng, H.; et al. Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome. Gastroenterology 2010, 139, 542-552. e3. [CrossRef] [PubMed]
118. Fiorentini, C.; Fabbri, A.; Falzano, L.; Fattorossi, A.; Matarrese, P.; Rivabene, R.; Donelli, G. Clostridium difficile toxin B induces apoptosis in intestinal cultured cells. Infect. Immun. 1998, 66, 2660-2665. [PubMed]
119. Brito, G. A.; Fujji, J.; Carneiro-Filho, B. A.; Lima, A. A.; Obrig, T.; Guerrant, R. L. Mechanism of Clostridium difficile toxin A-induced apoptosis in T84 cells. J. Infect. Dis. 2002, 186, 1438-1447. [CrossRef] [PubMed]
120. Hippenstiel, S.; Schmeck, B.; N'Guessan, P. D.; Seybold, J.; Krull, M.; Preissner, K.; Eichel-Streiber, C. V.; Suttorp, N. Rho protein inactivation induced apoptosis of cultured human endothelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2002, 283, L830-L838. [CrossRef] [PubMed]
121. Teichert, M.; Tatge, H.; Schoentaube, J.; Just, I.; Gerhard, R. Application of mutated Clostridium difficile toxin A for determination of glucosyltransferase-dependent effects. Infect. Immun. 2006, 74, 6006-6010. [CrossRef] [PubMed]
122. Nottrott, S.; Schoentaube, J.; Genth, H.; Just, I.; Gerhard, R. Clostridium difficile toxin A-induced apoptosis is p53-independent but depends on glucosylation of Rho GTPases. Apoptosis 2007, 12, 1443-1453. [CrossRef] [PubMed]
123. Gerhard, R.; Nottrott, S.; Schoentaube, J.; Tatge, H.; Olling, A.; Just, I. Glucosylation of Rho GTPases by Clostridium difficile toxin A triggers apoptosis in intestinal epithelial cells. J. Med. Microbiol. 2008, 57, 765-770. [CrossRef] [PubMed]
124. Mahida, Y. R.; Galvin, A.; Makh, S.; Hyde, S.; Sanfilippo, L.; Borriello, S. P.; Sewell, H. F. Effect of Clostridium difficile toxin A on human colonic lamina propria cells: Early loss of macrophages followed by T-cell apoptosis. Infect. Immun. 1998, 66, 5462-5469. [PubMed]
125. Qa'Dan, M.; Ramsey, M.; Daniel, J.; Spyres, L. M.; Safiejko-Mroczka, B.; Ortiz-Leduc, W.; Ballard, J. D. Clostridium difficile toxin B activates dual caspase-dependent and caspase-independent apoptosis in intoxicated cells. Cell. Microbiol. 2002, 4, 425-434. [CrossRef] [PubMed]
126. Matarrese, P.; Falzano, L.; Fabbri, A.; Gambardella, L.; Frank, C.; Geny, B.; Popoff, M. R.; Malorni, W.; Fiorentini, C. Clostridium difficile toxin B causes apoptosis in epithelial cells by thrilling mitochondria. Involvement of ATP-sensitive mitochondrial potassium channels. J. Biol. Chem. 2007, 282, 9029-9041. [CrossRef] [PubMed]
127. Wang, H.; Sun, X.; Zhang, Y.; Li, S.; Chen, K.; Shi, L.; Nie, W.; Kumar, R.; Tzipori, S.; Wang, J.; et al. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect. Immun. 2012, 80, 2678-2688. [CrossRef] [PubMed]
128. Sun, X.; Hirota, S. A. The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection. Mol. Immunol. 2015, 63, 193-202. [CrossRef] [PubMed]
129. Farrow, M. A.; Chumbler, N. M.; Lapierre, L. A.; Franklin, J. L.; Rutherford, S. A.; Goldenring, J. R.; Lacy, D. B. Clostridium difficile toxin B-induced necrosis is mediated by the host epithelial cell nadph oxidase complex. Proc. Natl. Acad. Sci. USA 2013, 110, 18674-18679. [CrossRef] [PubMed]
130. Wohlan, K.; Goy, S.; Olling, A.; Srivaratharajan, S.; Tatge, H.; Genth, H.; Gerhard, R. Pyknotic cell death induced by Clostridium difficile TcdB: Chromatin condensation and nuclear blister are induced independently of the glucosyltransferase activity. Cell. Microbiol. 2014, 16, 1678-1692. [CrossRef] [PubMed]
131. Xu, H.; Yang, J.; Gao, W.; Li, L.; Li, P.; Zhang, L.; Gong, Y. N.; Peng, X.; Xi, J. J.; Chen, S.; et al. Innate immune sensing of bacterial modifications of Rho GTPases by the pyrin inflammasome. Nature 2014, 513, 237-241. [CrossRef] [PubMed]
132. Lu, A.; Wu, H. Structural mechanisms of inflammasome assembly. FEBS J. 2015, 282, 435-444. [CrossRef] [PubMed]
133. Linevsky, J. K.; Pothoulakis, C.; Keates, S.; Warny, M.; Keates, A. C.; Lamont, J. T.; Kelly, C. P. IL-8 release and neutrophil activation by Clostridium difficile toxin-exposed human monocytes. Am. J. Physiol. 1997, 273, G1333-G1340. [PubMed]
134. Warny, M.; Keates, A. C.; Keates, S.; Castagliuolo, I.; Zacks, J. K.; Aboudola, S.; Qamar, A.; Pothoulakis, C.; LaMont, J. T.; Kelly, C. P. P38 map kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis. J. Clin. Investig. 2000, 105, 1147-1156. [CrossRef] [PubMed]
135. Ishida, Y.; Maegawa, T.; Kondo, T.; Kimura, A.; Iwakura, Y.; Nakamura, S.; Mukaida, N. Essential involvement of IFN-gamma in Clostridium difficile toxin A-induced enteritis. J. Immunol. 2004, 172, 3018-3025. [CrossRef] [PubMed]
136. Jafari, N. V.; Kuehne, S. A.; Bryant, C. E.; Elawad, M.; Wren, B. W.; Minton, N. P.; Allan, E.; Bajaj-Elliott, M. Clostridium difficile modulates host innate immunity via toxin-independent and dependent mechanism(s). PLoS ONE 2013, 8, e69846. [CrossRef] [PubMed]
137. Buonomo, E. L.; Madan, R.; Pramoonjago, P.; Li, L.; Okusa, M. D.; Petri, W. A., Jr. Role of interleukin 23 signaling in Clostridium difficile colitis. J. Infect. Dis. 2013, 208, 917-920. [CrossRef] [PubMed]
138. Cowardin, C. A.; Kuehne, S. A.; Buonomo, E. L.; Marie, C. S.; Minton, N. P.; Petri, W. A., Jr. Inflammasome activation contributes to interleukin-23 production in response to Clostridium difficile. MBio 2015. [CrossRef] [PubMed]
139. Lyerly, D. M.; Saum, K. E.; MacDonald, D. K.; Wilkins, T. D. Effects of Clostridium difficile toxins given intragastrically to animals. Infect. Immun. 1985, 47, 349-352. [PubMed]
140. Savidge, T. C.; Pan, W. H.; Newman, P.; O'Brien, M.; Anton, P. M.; Pothoulakis, C. Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine. Gastroenterology 2003, 125, 413-420. [CrossRef]
141. Riegler, M.; Sedivy, R.; Pothoulakis, C.; Hamilton, G.; Zacherl, J.; Bischof, G.; Cosentini, E.; Feil, W.; Schiessel, R.; LaMont, J. T.; et al. Clostridium difficile toxin B is more potent than toxin a in damaging human colonic epithelium in vitro. J. Clin. Investig. 1995, 95, 2004-2011. [CrossRef] [PubMed]
142. Aktories, K. Rho proteins: Targets for bacterial toxins. Trends Microbiol. 1997, 5, 282-288. [CrossRef]
143. Tucker, K. D.; Carrig, P. E.; Wilkins, T. D. Toxin A of Clostridium difficile is a potent cytotoxin. J. Clin. Microbiol. 1990, 28, 869-871. [PubMed]
144. Lyras, D.; O'Connor, J. R.; Howarth, P. M.; Sambol, S. P.; Carter, G. P.; Phumoonna, T.; Poon, R.; Adams, V.; Vedantam, G.; Johnson, S.; et al. Toxin Bb is essential for virulence of Clostridium difficile. Nature 2009, 458, 1176-1179. [CrossRef] [PubMed]
145. Kuehne, S. A.; Cartman, S. T.; Heap, J. T.; Kelly, M. L.; Cockayne, A.; Minton, N. P. The role of toxin A and toxin B in Clostridium difficile infection. Nature 2010, 467, 711-713. [CrossRef] [PubMed]
146. Kuehne, S. A.; Collery, M. M.; Kelly, M. L.; Cartman, S. T.; Cockayne, A.; Minton, N. P. Importance of toxin A, toxin B, and CDT in virulence of an epidemic Clostridium difficile strain. J. Infect. Dis. 2014, 209, 83-86. [CrossRef] [PubMed]
147. Steele, J.; Mukherjee, J.; Parry, N.; Tzipori, S. Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. J. Infect. Dis. 2013, 207, 323-330. [CrossRef] [PubMed]
148. Carter, G. P.; Chakravorty, A.; Nguyen, T. A. P.; Mileto, S.; Schreiber, F.; Li, L.; Howarth, P.; Clare, S.; Cunningham, B.; Sambol, S. P.; et al. Defining the roles of tcdA and tcdB in localized gastrointestinal disease, systemic organ damage, and the host response during Clostridium difficile infections. MBio. 2015, 6, e00551. [CrossRef] [PubMed]
149. Samra, Z.; Talmor, S.; Bahar, J. High prevalence of toxin A-negative toxin B-positive Clostridium difficile in hospitalized patients with gastrointestinal disease. Diagn. Microbiol. Infect. Dis. 2002, 43, 189-192. [CrossRef]
150. Carter, G. P.; Rood, J. I.; Lyras, D. The role of toxin A and toxin B in the virulence of Clostridium difficile. Trends Microbiol. 2012, 20, 21-29. [CrossRef] [PubMed]
151. McCoy, R. M.; Klick, A.; Hill, S.; Dull, R. B. Luminal toxin-binding agents for Clostridium difficile infection. J. Pharm. Pract. 2015. [CrossRef] [PubMed]
152. Weiss, K. Toxin-binding treatment for Clostridium difficile: A review including reports of studies with tolevamer. Int. J. Antimicrob. Agents 2009, 33, 4-7. [CrossRef] [PubMed]
153. Johnson, S.; Louie, T. J.; Gerding, D. N.; Cornely, O. A.; Chasan-Taber, S.; Fitts, D.; Gelone, S. P.; Broom, C.; Davidson, D. M. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: Results from two multinational, randomized, controlled trials. Clin. Infect. Dis. 2014, 59, 345-354. [CrossRef] [PubMed]
154. Mogg, G. A.; George, R. H.; Youngs, D.; Johnson, M.; Thompson, H.; Burdon, D. W.; Keighley, M. R. Randomized controlled trial of colestipol in antibiotic-associated colitis. Br. J. Surg. 1982, 69, 137-139. [CrossRef] [PubMed]
155. Sturino, J. M.; Pokusaeva, K.; Carpenter, R. Effective sequestration of Clostridium difficile protein toxins by calcium aluminosilicate. Antimicrob. Agents Chemother. 2015, 59, 7178-7183. [CrossRef] [PubMed]
156. Di Bella, S.; di Masi, A.; Turla, S.; Ascenzi, P.; Gouliouris, T.; Petrosillo, N. The protective role of albumin in Clostridium difficile infection: A step toward solving the puzzle. Infect. Control. Hosp. Epidemiol. 2015, 36, 1478-1479. [CrossRef] [PubMed]
157. Di Masi, A.; di Bella, S.; Turla, S.; Leboffe, L.; Arcovito, A.; Nocca, G.; Stano, P.; Ascenzi, P.; Petrosillo, N. Albumin prevents Clostridium difficile-related cytotoxicity through toxin B binding. In Proceedings of the ECCMID 2016, Amsterdam, The Netherlands, 11 April 2016.
158. Taylor, N. S.; Bartlett, J. G. Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins. J. Infect. Dis. 1980, 141, 92-97. [CrossRef] [PubMed]
159. Giesemann, T.; Guttenberg, G.; Aktories, K. Human alpha-defensins inhibit Clostridium difficile toxin B. Gastroenterology 2008, 134, 2049-2058. [CrossRef] [PubMed]
160. Bender, K. O.; Garland, M.; Ferreyra, J. A.; Hryckowian, A. J.; Child, M. A.; Puri, A. W.; Solow-Cordero, D. E.; Higginbottom, S. K.; Segal, E.; Banaei, N.; et al. A small-molecule antivirulence agent for treating Clostridium difficile infection. Sci. Transl. Med. 2015, 7, 306ra148. [CrossRef] [PubMed]
161. Tam, J.; Beilhartz, G. L.; Auger, A.; Gupta, P.; Therien, A. G.; Melnyk, R. A. Small molecule inhibitors of Clostridium difficile toxin B-induced cellular damage. Chem. Biol. 2015, 22, 175-185. [CrossRef] [PubMed]
162. Tsourous, G. I.; Raftopoulos, L. G.; Kafe, E. E.; Manoleris, E. K.; Makaritsis, K. P.; Pinis, S. G. A case of pseudomembranous colitis presenting with massive ascites. Eur. J. Intern. Med. 2007, 18, 328-330. [CrossRef] [PubMed]
163. Boaz, A.; Dan, M.; Charuzi, I.; Landau, O.; Aloni, Y.; Kyzer, S. Pseudomembranous colitis: Report of a severe case with unusual clinical signs in a young nurse. Dis. Colon Rectum. 2000, 43, 264-266. [CrossRef] [PubMed]
164. Siarakas, S.; Damas, E.; Murrell, W. G. Is cardiorespiratory failure induced by bacterial toxins the cause of sudden infant death syndrome? Studies with an animal model (the rabbit). Toxicon 1995, 33, 635-649. [CrossRef]
165. Sakurai, T.; Hajiro, K.; Takakuwa, H.; Nishi, A.; Aihara, M.; Chiba, T. Liver abscess caused by Clostridium difficile. Scand. J. Infect. Dis. 2001, 33, 69-70. [PubMed]
166. Shaikh, N.; Kettern, M. A.; Hanssens, Y.; Elshafie, S. S.; Louon, A. A rare and unsuspected complication of Clostridium difficile infection. Intensive Care Med. 2008, 34, 963-966. [CrossRef] [PubMed]
167. Jacob, S. S.; Sebastian, J. C.; Hiorns, D.; Jacob, S.; Mukerjee, P. K. Clostridium difficile and acute respiratory distress syndrome. Heart Lung 2004, 33, 265-268. [CrossRef] [PubMed]
168. Cunney, R. J.; Magee, C.; McNamara, E.; Smyth, E. G.; Walshe, J. Clostridium difficile colitis associated with chronic renal failure. Nephrol. Dial. Transplant. 1998, 13, 2842-2846. [CrossRef] [PubMed]
169. Surawicz, C. M.; Brandt, L. J.; Binion, D. G.; Ananthakrishnan, A. N.; Curry, S. R.; Gilligan, P. H.; McFarland, L. V.; Mellow, M.; Zuckerbraun, B. S. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am. J. Gastroenterol. 2013, 108, 478-498. [CrossRef] [PubMed]
170. Donta, S. T.; Sullivan, N.; Wilkins, T. D. Differential effects of Clostridium difficile toxins on tissue-cultured cells. J. Clin. Microbiol. 1982, 15, 1157-1158. [PubMed]
171. Qualman, S. J.; Petric, M.; Karmali, M. A.; Smith, C. R.; Hamilton, S. R. Clostridium difficile invasion and toxin circulation in fatal pediatric pseudomembranous colitis. Am. J. Clin. Pathol. 1990, 94, 410-416. [CrossRef] [PubMed]
172. He, X.; Wang, J.; Steele, J.; Sun, X.; Nie, W.; Tzipori, S.; Feng, H. An ultrasensitive rapid immunocytotoxicity assay for detecting Clostridium difficile toxins. J. Microbiol. Methods 2009, 78, 97-100. [CrossRef] [PubMed]
173. Steele, J.; Chen, K.; Sun, X.; Zhang, Y.; Wang, H.; Tzipori, S.; Feng, H. Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. J. Infect. Dis. 2012, 205, 384-391. [CrossRef] [PubMed]
174. Yu, H.; Chen, K.; Wu, J.; Yang, Z.; Shi, L.; Barlow, L. L.; Aronoff, D. M.; Garey, K. W.; Savidge, T. C.; von Rosenvinge, E. C.; et al. Identification of toxemia in patients with Clostridium difficile infection. PLoS ONE 2015, 10, e0124235. [CrossRef] [PubMed]
175. Kyne, L.; Warny, M.; Qamar, A.; Kelly, C. P. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med. 2000, 342, 390-397. [CrossRef] [PubMed]
176. Warny, M.; Vaerman, J. P.; Avesani, V.; Delmee, M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect. Immun. 1994, 62, 384-389. [PubMed]
177. Solomon, K.; Martin, A. J.; O'Donoghue, C.; Chen, X.; Fenelon, L.; Fanning, S.; Kelly, C. P.; Kyne, L. Mortality in patientswith Clostridiumdifficile infection correlateswith host pro-inflammatory and humoral immune responses. J. Med. Microbiol. 2013, 62, 1453-1460. [CrossRef] [PubMed]
178. Munoz, P.; Giannella, M.; Alcala, L.; Sarmiento, E.; Yanez, J. F.; Palomo, J.; Catalan, P.; Carbone, J.; Bouza, E. Clostridium difficile-associated diarrhea in heart transplant recipients: Is hypogammaglobulinemia the answer? J. Heart Lung Transplant. 2007, 26, 907-914. [CrossRef] [PubMed]
179. Johnson, S.; Kent, S. A.; O'Leary, K. J.; Merrigan, M. M.; Sambol, S. P.; Peterson, L. R.; Gerding, D. N. Fatal pseudomembranous colitis associated with a variant Clostridium difficile strain not detected by toxin A immunoassay. Ann. Intern. Med. 2001, 135, 434-438. [CrossRef] [PubMed]
180. Dobson, G.; Hickey, C.; Trinder, J. Clostridium difficile colitis causing toxic megacolon, severe sepsis and multiple organ dysfunction syndrome. Intensive Care Med. 2003, 29, 1030. [CrossRef] [PubMed]
181. Hamm, E. E.; Voth, D. E.; Ballard, J. D. Identification of Clostridium difficile toxin B cardiotoxicity using a zebrafish embryo model of intoxication. Proc. Natl. Acad. Sci. USA 2006, 103, 14176-14181. [CrossRef] [PubMed]
182. Torres, J.; Camorlinga-Ponce, M.; Muñoz, O. Sensitivity in culture of epithelial cells from rhesus monkey kidney and human colon carcinoma to toxins A and B from Clostridium difficile. Toxicon 1992, 30, 419-426. [CrossRef]
183. Anderson, R. J.; Ray, C. J.; Popoff, M. R. Evidence for rho protein regulation of renal tubular epithelial cell function. Kidney Int. 2000, 58, 1996-2006. [CrossRef] [PubMed]
184. Monteiro, H. S.; Santos-Neto, M. S.; Oliveira, A. V.; Lima, A. A.; Lyerly, D. M.; Fonteles, M. C. Vascular and glomerular effects of Clostridium difficile toxin A peptide on the isolated rat kidney. Braz. J. Med. Biol. Res. 1994, 27, 743-748. [PubMed]
185. Linseman, D. A.; Loucks, F. A. Diverse roles of Rho family GTPases in neuronal development, survival, and death. Front. Biosci. 2008, 13, 657-676. [CrossRef] [PubMed]
186. Loucks, F. A.; Le, S. S.; Zimmermann, A. K.; Ryan, K. R.; Barth, H.; Aktories, K.; Linseman, D. A. Rho family GTPase inhibition reveals opposing effects of mitogen-activated protein kinase kinase/extracellular signal-regulated kinase and janus kinase/signal transducer and activator of transcription signaling cascades on neuronal survival. J. Neurochem. 2006, 97, 957-967. [CrossRef] [PubMed]
187. Stankiewicz, T. R.; Loucks, F. A.; Schroeder, E. K.; Nevalainen, M. T.; Tyler, K. L.; Aktories, K.; Bouchard, R. J.; Linseman, D. A. Signal transducer and activator of transcription-5 mediates neuronal apoptosis induced by inhibition of Rac GTPase activity. J. Biol. Chem. 2012, 287, 16835-16848. [CrossRef] [PubMed]
188. Stankiewicz, T. R.; Ramaswami, S. A.; Bouchard, R. J.; Aktories, K.; Linseman, D. A. Neuronal apoptosis induced by selective inhibition of Rac GTPase versus global suppression of Rho family GTPases is mediated by alterations in distinct mitogen-activated protein kinase signaling cascades. J. Biol. Chem. 2015, 290, 9363-9376. [CrossRef] [PubMed]